within Pharmacolibrary.Drugs.ATC.A;

model A12AA30
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.7 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,
    adminCount     = 1,
    Vd             = 0.00011999999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Calcium laevulate is a calcium salt of levulinic acid, used as a calcium supplement in pharmaceutical formulations. It is designed to address calcium deficiency or as an adjunct in situations where enhanced calcium intake is required. There is no evidence that calcium laevulate is widely approved or commonly used today, and no specific regulatory status is noted in current pharmacopeias.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic parameter data available for calcium laevulate in humans or animals in the literature.</p><h4>References</h4><ol><li><p>Sharma, P, et al., &amp; Nanda, S (2020). Cubosome: A Potential Liquid Crystalline Carrier System. <i>Current pharmaceutical design</i> 26(27) 3300–3316. DOI:<a href=&quot;https://doi.org/10.2174/1381612826666200617162424&quot;>10.2174/1381612826666200617162424</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32552637/&quot;>https://pubmed.ncbi.nlm.nih.gov/32552637</a></p></li><li><p>Yadav, V, et al., &amp; Basit, AW (2021). 5-Aminolevulinic Acid as a Novel Therapeutic for Inflammatory Bowel Disease. <i>Biomedicines</i> 9(5) –. DOI:<a href=&quot;https://doi.org/10.3390/biomedicines9050578&quot;>10.3390/biomedicines9050578</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34065300/&quot;>https://pubmed.ncbi.nlm.nih.gov/34065300</a></p></li><li><p>Sun, P, et al., &amp; Fang, L (2024). Deep eutectic solvent combined with permeation enhancer strategy to convert tandospirone from oral to transdermal formulations improving drug bioavailability. <i>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</i> 205 114570–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ejpb.2024.114570&quot;>10.1016/j.ejpb.2024.114570</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39490429/&quot;>https://pubmed.ncbi.nlm.nih.gov/39490429</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A12AA30;
